U.S. markets open in 8 hours 4 minutes

Fulcrum Therapeutics, Inc. (FULC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
8.59+0.02 (+0.23%)
At close: 4:00PM EDT

Fulcrum Therapeutics, Inc.

26 Landsdowne Street
Cambridge, MA 02139
United States
617 651 8851

Full Time Employees73

Key Executives

NameTitlePayExercisedYear Born
Mr. Mark J. LevinExec. Chairman73kN/A1950
Mr. Bryan E. StuartPres, CEO & Director598.4kN/A1976
Mr. Curtis G. Oltmans J.D.Sr. VP, Gen. Counsel & Corp. Sec.83.98kN/A1963
Dr. Bradley E. BernsteinFounderN/AN/AN/A
Dr. Michael R. GreenFounderN/AN/AN/A
Dr. Rudolf Jaenisch Ph.D., M.D.FounderN/AN/AN/A
Prof. Jeannie T. Lee M.D., Ph.D.FounderN/AN/AN/A
Dr. Danny ReinbergFounderN/AN/AN/A
Mr. Peter G. ThomsonVP of Fin. & AccountingN/AN/AN/A
Dr. Christopher Moxham Ph.D.Chief Scientific OfficerN/AN/A1968
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and ß-thalassemia. The company is also discovering drug targets for the treatments of muscle, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Fulcrum Therapeutics, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 9. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.